Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2018 | Apr. 20, 2018 | |
Document Information [Line Items] | ||
Entity Registrant Name | PSYCHEMEDICS CORP | |
Entity Central Index Key | 806,517 | |
Trading Symbol | pmd | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 5,492,053 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Current Assets: | ||
Cash and cash equivalents | $ 8,284 | $ 8,165 |
Accounts receivable, net of allowance for doubtful accounts of $69 in 2018 and $64 in 2017 | 6,062 | 4,488 |
Prepaid expenses and other current assets | 1,197 | 1,212 |
Total Current Assets | 15,543 | 13,865 |
Fixed Assets, net of accumulated amortization and depreciation of $12,414 in 2018 and $11,670 in 2017 | 11,289 | 11,811 |
Other assets | 897 | 832 |
Total Assets | 27,729 | 26,508 |
Current Liabilities: | ||
Accounts payable | 327 | 398 |
Accrued expenses | 3,888 | 2,870 |
Current portion of long-term debt | 957 | 957 |
Total Current Liabilities | 5,172 | 4,225 |
Long-term debt | 2,181 | 2,420 |
Deferred tax liabilities, long-term | 1,205 | 1,243 |
Total Liabilities | 8,558 | 7,888 |
Commitments and Contingencies (Note 7) | ||
Shareholders' Equity: | ||
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding | ||
Common stock, $0.005 par value; 50,000 shares authorized 6,160 shares issued in 2018 and 2017 | 31 | 31 |
Accumulated other comprehensive loss | (250) | (238) |
Additional paid-in capital | 31,157 | 31,022 |
Accumulated deficit | (1,685) | (2,113) |
Less - Treasury stock, at cost, 668 shares | (10,082) | (10,082) |
Total Shareholders' Equity | 19,171 | 18,620 |
Total Liabilities and Shareholders' Equity | $ 27,729 | $ 26,508 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Allowance for doubtful accounts | $ 69 | $ 64 |
Accumulated amortization and depreciation | $ 12,414 | $ 11,670 |
Preferred stock, par value (in dollars per share) | $ 0.005 | $ 0.005 |
Preferred stock, shares authorized (in shares) | 873 | 873 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.005 | $ 0.005 |
Common stock, shares authorized (in shares) | 50,000 | 50,000 |
Common stock, shares issued (in shares) | 6,160 | 6,160 |
Treasury stock, shares (in shares) | 668 | 668 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Revenues | $ 10,935 | $ 10,209 |
Cost of revenues | 5,580 | 4,893 |
Gross profit | 5,355 | 5,316 |
Operating Expenses: | ||
General & administrative | 1,851 | 1,475 |
Marketing & selling | 1,239 | 1,243 |
Research & development | 359 | 330 |
Total Operating Expenses | 3,449 | 3,048 |
Operating income | 1,906 | 2,268 |
Other income (expense) | 32 | (22) |
Net income before provision for income taxes | 1,938 | 2,246 |
Provision for income taxes | 687 | 746 |
Net income | 1,251 | 1,500 |
Other Comprehensive Income (Loss): | ||
Foreign currency translation | (12) | |
Total Comprehensive Income | $ 1,239 | $ 1,500 |
Basic net income per share (in dollars per share) | $ 0.23 | $ 0.27 |
Diluted net income per share (in dollars per share) | 0.23 | 0.27 |
Dividends declared per share (in dollars per share) | $ 0.18 | $ 0.15 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ 1,251 | $ 1,500 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 753 | 687 |
Deferred income taxes | (38) | (55) |
Stock-based compensation | 135 | 163 |
Changes in assets and liabilities: | ||
Accounts receivable | (1,575) | 2,050 |
Prepaid expenses, other current assets, and income tax receivable | 15 | (92) |
Accounts payable | (116) | (752) |
Accrued expenses and accrued income taxes | 981 | 901 |
Net cash provided by operating activities | 1,406 | 4,402 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchases of equipment and leasehold improvements | (144) | (153) |
Cost of internally developed software | (210) | |
Other assets | (74) | (3) |
Net cash used in investing activities | (218) | (366) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Payments of equipment financing | (239) | (286) |
Cash dividends paid | (824) | (819) |
Net cash used in financing activities | (1,063) | (1,105) |
Effect of exchange rate changes on cash and cash equivalents | (6) | |
Net increase / (decrease) in cash and cash equivalents | 119 | 2,931 |
Cash and cash equivalents, beginning of period | 8,165 | 3,938 |
Cash and cash equivalents, end of period | 8,284 | 6,869 |
Supplemental Disclosures of Cash Flow Information: | ||
Cash paid for income taxes | 370 | 29 |
Cash paid for interest | 28 | 22 |
Purchases of equipment through accounts payable and accrued liabilities | $ 25 | $ 11 |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Basis of Presentation The interim condensed consolidated financial statements of Psychemedics Corporation (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10 not December 31, 2017, 2017 10 The condensed consolidated balance sheet as of March 31, 2018, three March 31, 2018 2017, three March 31, 2018 2017 December 31, 2017 not The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three March 31, 2018 may not may December 31, 2018, Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to Psychemedics Corporation and its consolidated subsidiaries. |
Note 2 - Cash and Cash Equivale
Note 2 - Cash and Cash Equivalents | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Cash and Cash Equivalents Disclosure [Text Block] | 2. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of 90 |
Note 3 - Stock-based Compensati
Note 3 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 3. Stock-Based Compensation The Company’s 2006 March 31, 2018, 199 A summary of the Company’s stock option activity for the three March 31, 2018 000’s Weighted Average Weighted Average Aggregate (1) Outstanding, December 31, 2017 279 $ 15.40 8.7 years $ 1,436 Granted - Exercised - Forfeited - Outstanding, March 31, 2018 279 $ 15.40 8.4 years $ 1,659 Exercisable, March 31, 2018 56 $ 12.61 7.9 years $ 491 ( 1 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company’s stock on March 31, 2018 ( $21.36 A summary of the Company’s stock unit award activity for the three March 31, 2018 000’s Number of Shares Weighted Average Price per Share (2) Weighted Average Fair Value (2) Outstanding & Unvested, December 31, 2017 32 $ 16.08 $ 516 Granted - Converted to common stock - Cancelled - Forfeited - Outstanding & Unvested, March 31, 2018 32 $ 16.08 $ 516 ( 2 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares. As of March 31, 2018, 510 March 31, 2018, $0.8 2.7 |
Note 4 - Basic and Diluted Net
Note 4 - Basic and Diluted Net Income Per Share | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Basic and Diluted Net Income Per Share Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted average number of common and dilutive common equivalent shares outstanding during the period. The number of dilutive common equivalent shares outstanding during the period was determined in accordance with the treasury-stock method. Common equivalent shares consisted of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the three March 31, 2018 2017 Three Months Ended March 31, March 31, Weighted average common shares outstanding, basic 5,492 5,460 Dilutive common equivalent shares 64 73 Weighted average common shares outstanding, diluted 5,556 5,533 |
Note 5 - Business Segment Repor
Note 5 - Business Segment Reporting | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 5. Business Segment Reporting The Company manages its operations as one one 10% Three Months Ended March 31, March 31, Consolidated Revenue: United States $ 7,323 $ 6,468 Brazil 3,526 3,696 Other 86 45 Total Revenue $ 10,935 $ 10,209 |
Note 6 - Fair Value Measurement
Note 6 - Fair Value Measurements | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 6. Fair Value Measurements The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, which are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company. |
Note 7 - Subsequent Events
Note 7 - Subsequent Events | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 7. Subsequent Events On April 24, 2018, $0.18 $989 May 18, 2018 May 8, 2018 |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 8. Commitments and Contingencies The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. While the ultimate outcome of individual legal claims is inherently unpredictable, we believe that the final resolution of any pending actions will not |
Note 9 - Debt and Other Financi
Note 9 - Debt and Other Financing Agreements | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 9. Debt and Other Financing Arrangements On March 20, 2014, August 8, 2014, September 15, 2015 October 30, 2017. 10 The weighted average interest rate for all notes related to the Loan Agreement for the quarter ended March 31, 2018 3.4%, $28 2.8% $22 2017. March 31, 2018, 3.5% $3.1 March 31, 2018. The annual principal repayment requirements for debt obligations as of March 31, 2018 000’s 2018 $ 718 2019 891 2020 702 2021 446 2022 381 Total long-term debt 3,138 Less current portion of long-term debt (957 ) Total long-term debt, net of current portion $ 2,181 |
Note 10 - Significant Customers
Note 10 - Significant Customers | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | 10. Significant Customers The Company had one 32% three March 31, 2018 36% three March 31, 2017. two 10% March 31, 2018 one 10% December 31, 2017. |
Note 11 - Recently Adopted Acco
Note 11 - Recently Adopted Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
New Accounting Pronouncements and Changes in Accounting Principles [Text Block] | 11. Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, 605, Effective January 1, 2018, 606, January 1, 2018. 606 not 13 |
Note 12 - Accounting Pronouncem
Note 12 - Accounting Pronouncements Issued But Not Yet Effective | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | 12. Accounting Pronouncements Issued But Not In February 2016, 2016 02, 12 December 15, 2018 In February 2018, 2018 02, 220 2018 2, not 2018 02 2020, In March 2018, 2018 05, 740 No. 118”, December 22, 2017, |
Note 13 - Revenue
Note 13 - Revenue | 3 Months Ended |
Mar. 31, 2018 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 13. Revenue Adoption of ASC Topic 606, On January 1, 2018, 606 606 not Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source. For additional revenue detail relating to geographic breakdown of sales, see Note 5 Three Months Ended March 31, March 31, (in 000's) Testing $ 9,997 $ 9,385 Shipping/Collection (hair) 824 684 Other 114 140 Total Revenue $ 10,935 $ 10,209 Testing Revenue Testing revenue is our primary service. This primarily represents drug and alcohol tests for drugs of abuse using hair, performed in our forensic laboratory in California. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration we expect to receive in exchange for providing services. Sales and other taxes we pay concurrent with revenue-producing activities are excluded from revenue. Incidental items, such as storage of samples and data, that are immaterial in the context of the contract are recognized as expense. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (“sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration we expect to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including; urine testing performed by other labs, medical review officer charges, legal/testifying services, a retail test which is sent to the laboratory for testing, and other miscellaneous charges. The total of all of these items is approximately 1% Practical Expedients and Exemptions We generally expense sales commissions when incurred because the amortization period is one |
Note 3 - Stock-based Compensa19
Note 3 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes Tables | |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Weighted Average Weighted Average Aggregate (1) Outstanding, December 31, 2017 279 $ 15.40 8.7 years $ 1,436 Granted - Exercised - Forfeited - Outstanding, March 31, 2018 279 $ 15.40 8.4 years $ 1,659 Exercisable, March 31, 2018 56 $ 12.61 7.9 years $ 491 |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Number of Shares Weighted Average Price per Share (2) Weighted Average Fair Value (2) Outstanding & Unvested, December 31, 2017 32 $ 16.08 $ 516 Granted - Converted to common stock - Cancelled - Forfeited - Outstanding & Unvested, March 31, 2018 32 $ 16.08 $ 516 |
Note 4 - Basic and Diluted Ne20
Note 4 - Basic and Diluted Net Income Per Share (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes Tables | |
Schedule of Weighted Average Number of Shares [Table Text Block] | Three Months Ended March 31, March 31, Weighted average common shares outstanding, basic 5,492 5,460 Dilutive common equivalent shares 64 73 Weighted average common shares outstanding, diluted 5,556 5,533 |
Note 5 - Business Segment Rep21
Note 5 - Business Segment Reporting (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes Tables | |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended March 31, March 31, Consolidated Revenue: United States $ 7,323 $ 6,468 Brazil 3,526 3,696 Other 86 45 Total Revenue $ 10,935 $ 10,209 |
Note 9 - Debt and Other Finan22
Note 9 - Debt and Other Financing Agreements (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes Tables | |
Schedule of Long-term Debt Instruments [Table Text Block] | 2018 $ 718 2019 891 2020 702 2021 446 2022 381 Total long-term debt 3,138 Less current portion of long-term debt (957 ) Total long-term debt, net of current portion $ 2,181 |
Note 13 - Revenue (Tables)
Note 13 - Revenue (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended March 31, March 31, (in 000's) Testing $ 9,997 $ 9,385 Shipping/Collection (hair) 824 684 Other 114 140 Total Revenue $ 10,935 $ 10,209 |
Note 3 - Stock-based Compensa24
Note 3 - Stock-based Compensation (Details Textual) $ / shares in Units, shares in Thousands, $ in Millions | 3 Months Ended |
Mar. 31, 2018USD ($)$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 199 |
Share Price | $ / shares | $ 21.36 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $ | $ 0.8 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 255 days |
Stock Incentive Plan 2006 [Member] | |
Common Stock, Capital Shares Reserved for Future Issuance | 510 |
Note 3 - Stock-based Compensa25
Note 3 - Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2018 | Dec. 31, 2017 | ||
Outstanding (in shares) | 279 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 15.40 | ||
Outstanding, Weighted average remaining contractual life (Year) | 8 years 146 days | 8 years 255 days | |
Outstanding, aggregate intrinsic value | [1] | $ 1,659 | $ 1,436 |
Granted (in shares) | |||
Granted, weighted average exercise price (in dollars per share) | |||
Exercised (in shares) | |||
Exercised, weighted average exercise price (in dollars per share) | |||
Forfeited (in shares) | |||
Forfeited, weighted average exercise price (in dollars per share) | |||
Outstanding (in shares) | 279 | 279 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 15.40 | $ 15.40 | |
Exercisable (in shares) | 56 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 12.61 | ||
Exercisable, Weighted average remaining contractual life (Year) | 7 years 328 days | ||
Exercisable, aggregate intrinsic value | [1] | $ 491 | |
[1] | The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market value of the Company's stock on March 31, 2018 ($21.36) exceeded the exercise price of the underlying options, multiplied by the number of shares subject to each option. |
Note 3 - Share-based Compensati
Note 3 - Share-based Compensation - Nonvested Award Activity (Details) - Stock Unit Award [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | ||
Mar. 31, 2018 | Dec. 31, 2017 | ||
Outstanding & Unvested (in shares) | 32 | ||
Outstanding & Unvested, weighted average price per share (in dollars per share) | [1] | $ 16.08 | |
Outstanding & Unvested, weighted average fair value | [1] | $ 516 | $ 516 |
Granted (in shares) | |||
Granted, weighted average price per share (in dollars per share) | [1] | ||
Granted, weighted average fair value | [1] | ||
Converted to common stock (in shares) | |||
Cancelled (in shares) | |||
Forfeited (in shares) | |||
Outstanding & Unvested (in shares) | 32 | ||
Outstanding & Unvested, weighted average price per share (in dollars per share) | [1] | $ 16.08 | |
[1] | Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each grant of stock unit awards. The weighted average fair value is the weighted average share price times the number of shares. |
Note 4 - Basic and Diluted Ne27
Note 4 - Basic and Diluted Net Income Per Share - Basic and Diluted Shares Outstanding (Details) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Weighted average common shares outstanding, basic (in shares) | 5,492 | 5,460 |
Dilutive common equivalent shares (in shares) | 64 | 73 |
Weighted average common shares outstanding, diluted (in shares) | 5,556 | 5,533 |
Note 5 - Business Segment Rep28
Note 5 - Business Segment Reporting (Details Textual) | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Number of Operating Segments | 1 | |
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | ||
Number of Major Customers | 1 | 1 |
Concentration Risk, Percentage | 32.00% | 36.00% |
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | BRAZIL | ||
Number of Major Customers | 1 | |
Concentration Risk, Percentage | 10.00% |
Note 5 - Business Segment Rep29
Note 5 - Business Segment Reporting - Summary of Revenues by Geographic Region (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Revenues | $ 10,935 | $ 10,209 |
UNITED STATES | ||
Revenues | 7,323 | 6,468 |
BRAZIL | ||
Revenues | 3,526 | 3,696 |
Other Foreign Countries [Member] | ||
Revenues | $ 86 | $ 45 |
Note 7 - Subsequent Events (Det
Note 7 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions | Apr. 24, 2018 | Mar. 31, 2018 | Mar. 31, 2017 |
Common Stock, Dividends, Per Share, Declared | $ 0.18 | $ 0.15 | |
Subsequent Event [Member] | |||
Common Stock, Dividends, Per Share, Declared | $ 0.18 | ||
Dividends Payable | $ 989 | ||
Dividends Payable, Date to be Paid | May 18, 2018 | ||
Dividends Payable, Date of Record | May 8, 2018 |
Note 9 - Debt and Other Finan31
Note 9 - Debt and Other Financing Agreements (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Debt, Weighted Average Interest Rate | 3.40% | 2.80% |
Interest Expense, Total | $ 28 | $ 22 |
Debt Instrument, Interest Rate, Effective Percentage | 3.50% | |
Long-term Debt, Total | $ 3,138 |
Note 9 - Debt and Other Finan32
Note 9 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
2,018 | $ 718 | |
2,019 | 891 | |
2,020 | 702 | |
2,021 | 446 | |
2,022 | 381 | |
Total long-term debt | 3,138 | |
Less current portion of long-term debt | (957) | $ (957) |
Total long-term debt, net of current portion | $ 2,181 | $ 2,420 |
Note 10 - Significant Custome33
Note 10 - Significant Customers (Details Textual) - Customer Concentration Risk [Member] | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | |
Sales Revenue, Net [Member] | |||
Number of Major Customers | 1 | 1 | |
Concentration Risk, Percentage | 32.00% | 36.00% | |
Accounts Receivable [Member] | |||
Number of Major Customers | 2 | 1 |
Note 13 - Revenue (Details Text
Note 13 - Revenue (Details Textual) | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Sales Revenue, Net [Member] | Product Concentration Risk [Member] | Other Revenue [Member] | ||
Concentration Risk, Percentage | 1.00% | 1.00% |
Note 13 - Revenue - Revenue by
Note 13 - Revenue - Revenue by Major Source (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Revenues | $ 10,935 | $ 10,209 |
Testing [Member] | ||
Revenues | 9,997 | 9,385 |
Shipping/Collection (Hair) [Member] | ||
Revenues | 824 | 684 |
Other Revenue [Member] | ||
Revenues | $ 114 | $ 140 |